World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
53669
World Ranking
13380
National Ranking
422

Overview

David Planchard is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on the fields of Medicine, with significant contributions to Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their work covers major topics including Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, and HER2/EGFR in Cancer Research.

Planchard has contributed to several recent scientific papers, such as:

  • "Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC" (2023, New England Journal of Medicine)
  • "Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer" (2021, New England Journal of Medicine)
  • "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023, Annals of Oncology)
  • "Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer" (2022, Nature Medicine)
  • "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023, Annals of Oncology)

Frequent co-authors include Benjamin Besse, Mihaela Aldea, Fabrice Barlési, Laura Mezquita, and Jordi Remón.

Planchard publishes regularly in venues such as:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Lung Cancer

Best Publications

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Scott J Antonia;Augusto Villegas;Davey Daniel;David Vicente

  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    Scott J. Antonia;Augusto Villegas;Davey Daniel;David Vicente

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

    Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

    Laura Mezquita;Edouard Auclin;Roberto Ferrara;Melinda Charrier

  • Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

    Kathryn C. Arbour;Laura Mezquita;Niamh Long;Hira Rizvi

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

    Roberto Ferrara;Laura Mezquita;Matthieu Texier;Jihene Lahmar

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

    James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  • Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

    Arnaud Scherpereel;Julien Mazieres;Laurent Greillier;Sylvie Lantuejoul

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

  • A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

    F Farace;F Farace;C Massard;N Vimond;F Drusch

  • Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer

    A Lecharpentier;P Vielh;P Perez-Moreno;D Planchard

  • Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

    Myriam Delaunay;Jacques Cadranel;Amélie Lusque;Nicolas Meyer

  • Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

    Jhanelle E. Gray;Augusto Villegas;Davey Daniel;David Vicente

Frequent Co-Authors

Benjamin Besse
Benjamin Besse University of Paris-Saclay
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Julien Mazieres
Julien Mazieres Paul Sabatier University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Nathalie Chaput
Nathalie Chaput Institut Gustave Roussy
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Pasi A. Jänne
Pasi A. Jänne Harvard University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Scott J. Antonia
Scott J. Antonia Duke University
Silvia Novello
Silvia Novello University of Turin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in health careers but not ready to commit to the full journey of medical school, numerous online degree options offer rewarding pathways in healthcare. Many reputable universities now offer a him degree online, which prepares students for critical roles in maintaining and managing patient data—an increasingly important field as healthcare systems move to digital platforms.

Another popular career track is medical coding and billing. By earning a medical billing and coding certification online, you can quickly enter the workforce and play a key role in healthcare administration. For nurses looking to advance their expertise, affordable cheap online fnp programs enable registered nurses to expand their practice and become family nurse practitioners.

Likewise, existing RNs can benefit from the cheapest rn to bsn online programs, opening up leadership roles and advancing their careers without leaving their jobs. With flexible schedules and lower costs, these programs offer practical, accessible routes into vital healthcare professions.

Best Scientists Citing David Planchard

Trending Scientists

Recently Published Articles